New Migraine Treatment Shows Promise for Tough Cases

For the 431 patients in this study who had already tried and failed other migraine prevention treatments, new hope just arrived in the form of an experimental IV antibody.

Danish pharmaceutical company Lundbeck announced that its drug bocunebart met the main goal of a phase 2b trial. Patients receiving the treatment experienced fewer monthly migraine days over 12 weeks compared to those on placebo, and the difference was statistically significant.

The drug was also well tolerated by patients, an important consideration for anyone managing chronic migraines. Lundbeck plans to share detailed data at an upcoming medical conference and discuss phase 3 trial designs with regulators.

What makes this treatment different is its novel approach. Bocunebart targets PACAP, a protein involved in migraine attacks, making it the first drug of its kind. If approved, it would give doctors a new tool for patients who haven't responded to current prevention options.

The journey to this success had a detour. The trial originally tested both IV and injection delivery methods, but Lundbeck stopped the injection portion last year after data showed it wasn't working well enough. This decision to focus on IV administration alone proved to be the right call.

The Bright Side

Migraine prevention is an especially crowded field right now, which means more options for patients. Lundbeck already markets Vyepti, another IV migraine drug that brought in $710 million last year with 59% growth. The success of these treatments reflects genuine progress in understanding and treating a condition that affects millions.

The PACAP approach has been tricky for other companies. Both Amgen and Eli Lilly stopped development of similar drugs after disappointing results. But Lundbeck's success with the IV method shows that finding the right delivery approach can make all the difference.

For people living with severe migraines who cycle through treatments looking for relief, this trial represents something concrete. It's not just another drug in development but one that has proven it can reduce migraine frequency in a real patient population.

The company will now work with health regulators to design phase 3 trials, the final step before potential approval.